 | • レポートコード：MRC2305A091 • 出版社/出版日：Transparency Market Research / 2023年3月29日 • レポート形態：英文、PDF、235ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートによると、世界の強心薬市場規模が、2023年の732百万ドルから2031年に45億ドルとなり、予測期間中に年平均21.3%で成長すると推測されています。本レポートは、強心薬の世界市場について徹底的に分析・調査を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤別（ジギタリス配糖体、ホスホジエステラーゼ阻害剤、心保護薬、交感神経刺激薬、その他）分析、用途別（心臓外科手術、心房細動、心不全、肺高血圧症、その他）分析、投与経路別（経口、非経口）分析、剤形別（錠剤、液体、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の項目を整理しています。また、Amneal Pharmaceuticals LLC、Pfizer Inc.、Hikma Pharmaceuticals PLC、Fresenius Kabi、Midas Pharma GmbH、Sanofi、Aurobindo Pharma Limited、SimSon Pharma Limited、Other Playersなど、主要企業情報を含んでいます。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の強心薬市場規模：薬剤別 - ジギタリス配糖体の市場規模 - ホスホジエステラーゼ阻害剤の市場規模 - 心保護薬の市場規模 - 交感神経刺激薬の市場規模 - その他薬剤の市場規模 ・世界の強心薬市場規模：用途別 - 心臓外科手術における市場規模 - 心房細動における市場規模 - 心不全における市場規模 - 肺高血圧症における市場規模 - その他用途における市場規模 ・世界の強心薬市場規模：投与経路別 - 経口における市場規模 - 非経口投与における市場規模 ・世界の強心薬市場規模：剤形別 - 錠剤における市場規模 - 液体における市場規模 - その他剤型における市場規模 ・世界の強心薬市場規模：地域別 - 北米の強心薬市場規模 - ヨーロッパの強心薬市場規模 - アジア太平洋の強心薬市場規模 - 中南米の強心薬市場規模 - 中東・アフリカの強心薬市場規模 ・競争状況 |
Cardiotonic Agents Market – Scope of Report
TMR’s report on the global cardiotonic agents market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cardiotonic agents market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiotonic agents market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cardiotonic agents market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiotonic agents market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiotonic agents market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiotonic agents market.
The report delves into the competitive landscape of the global cardiotonic agents market. Key players operating in the global cardiotonic agents market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiotonic agents market profiled in this report.
Key Questions Answered in Global Cardiotonic Agents Market Report
• What is the sales/revenue generated by cardiotonic agents across all regions during the forecast period?
• What are the opportunities in the global cardiotonic agents market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Cardiotonic Agents Market – Research Objectives and Research Approach
The comprehensive report on the global cardiotonic agents market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global cardiotonic agents market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiotonic agents market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiotonic Agents Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiotonic Agents Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Industry Events
5.2. Technological Advancements
5.3. Value Chain Analysis
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Cardiotonic Agents Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Digitalis Glycosides
6.3.2. Phosphodiesterase Inhibitors
6.3.3. Cardioprotectants
6.3.4. Sympathomimetic Agents
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Cardiotonic Agents Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Cardiac Surgical Procedures
7.3.2. Atrial Fibrillation
7.3.3. Heart Failure
7.3.4. Pulmonary Hypertension
7.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
7.4. Market Attractiveness Analysis, by Application
8. Global Cardiotonic Agents Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Cardiotonic Agents Market Analysis and Forecast, by Dosage Form
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Dosage Form, 2017–2031
9.3.1. Tablet
9.3.2. Solution
9.3.3. Others
9.4. Market Attractiveness Analysis, by Dosage Form
10. Global Cardiotonic Agents Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Cardiotonic Agents Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Cardiotonic Agents Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Digitalis Glycosides
12.2.2. Phosphodiesterase Inhibitors
12.2.3. Cardioprotectants
12.2.4. Sympathomimetic Agents
12.2.5. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Cardiac Surgical Procedures
12.3.2. Atrial Fibrillation
12.3.3. Heart Failure
12.3.4. Pulmonary Hypertension
12.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Dosage Form, 2017–2031
12.5.1. Tablet
12.5.2. Solution
12.5.3. Others
12.6. Market Value Forecast, by Distribution Channel, 2017–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Type
12.8.2. By Application
12.8.3. By Route of Administration
12.8.4. By Dosage Form
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Cardiotonic Agents Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Digitalis Glycosides
13.2.2. Phosphodiesterase Inhibitors
13.2.3. Cardioprotectants
13.2.4. Sympathomimetic Agents
13.2.5. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Cardiac Surgical Procedures
13.3.2. Atrial Fibrillation
13.3.3. Heart Failure
13.3.4. Pulmonary Hypertension
13.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Dosage Form, 2017–2031
13.5.1. Tablet
13.5.2. Solution
13.5.3. Others
13.6. Market Value Forecast, by Distribution Channel, 2017–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Type
13.8.2. By Application
13.8.3. By Route of Administration
13.8.4. By Dosage Form
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Cardiotonic Agents Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2031
14.2.1. Digitalis Glycosides
14.2.2. Phosphodiesterase Inhibitors
14.2.3. Cardioprotectants
14.2.4. Sympathomimetic Agents
14.2.5. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Cardiac Surgical Procedures
14.3.2. Atrial Fibrillation
14.3.3. Heart Failure
14.3.4. Pulmonary Hypertension
14.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Dosage Form, 2017–2031
14.5.1. Tablet
14.5.2. Solution
14.5.3. Others
14.6. Market Value Forecast, by Distribution Channel, 2017–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Type
14.8.2. By Application
14.8.3. By Route of Administration
14.8.4. By Dosage Form
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Cardiotonic Agents Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2017–2031
15.2.1. Digitalis Glycosides
15.2.2. Phosphodiesterase Inhibitors
15.2.3. Cardioprotectants
15.2.4. Sympathomimetic Agents
15.2.5. Others
15.3. Market Value Forecast, by Application, 2017–2031
15.3.1. Cardiac Surgical Procedures
15.3.2. Atrial Fibrillation
15.3.3. Heart Failure
15.3.4. Pulmonary Hypertension
15.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Dosage Form, 2017–2031
15.5.1. Tablet
15.5.2. Solution
15.5.3. Others
15.6. Market Value Forecast, by Distribution Channel, 2017–2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Type
15.8.2. By Application
15.8.3. By Route of Administration
15.8.4. By Dosage Form
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Cardiotonic Agents Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Type, 2017–2031
16.2.1. Digitalis Glycosides
16.2.2. Phosphodiesterase Inhibitors
16.2.3. Cardioprotectants
16.2.4. Sympathomimetic Agents
16.2.5. Others
16.3. Market Value Forecast, by Application, 2017–2031
16.3.1. Cardiac Surgical Procedures
16.3.2. Atrial Fibrillation
16.3.3. Heart Failure
16.3.4. Pulmonary Hypertension
16.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
16.4. Market Value Forecast, by Route of Administration, 2017–2031
16.4.1. Oral
16.4.2. Parenteral
16.5. Market Value Forecast, by Dosage Form, 2017–2031
16.5.1. Tablet
16.5.2. Solution
16.5.3. Others
16.6. Market Value Forecast, by Distribution Channel, 2017–2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Type
16.8.2. By Application
16.8.3. By Route of Administration
16.8.4. By Dosage Form
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. Amneal Pharmaceuticals LLC
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Pfizer Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Hikma Pharmaceuticals PLC
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Fresenius Kabi
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Midas Pharma GmbH
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Sanofi
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Aurobindo Pharma Limited
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. SimSon Pharma Limited
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Other Players
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview